CCDC42B Inhibitors
Chemical inhibitors of the protein CCDC42B operate through various mechanisms to impede its function within cellular processes. Staurosporine, as a broad-spectrum kinase inhibitor, blocks the phosphorylation events crucial for the activity of this protein, thereby inhibiting its function. Similar in its approach, Bisindolylmaleimide I specifically targets Protein Kinase C (PKC), a kinase with a regulatory role over CCDC42B. SP600125 and SB203580 target different kinases in the mitogen-activated protein kinase (MAPK) pathways-c-Jun N-terminal kinase (JNK) and p38 MAP kinase, respectively. Inhibition by SP600125 can disrupt CCDC42B's involvement in JNK-related cellular processes. SB203580's inhibition of p38 MAP kinase can similarly interrupt the signaling pathways that require CCDC42B's participation, effectively inhibiting its function.
Further targeting the signaling pathways that CCDC42B may rely on, LY294002 and Wortmannin exert their effects by inhibiting phosphoinositide 3-kinases (PI3K). The prevention of PI3K activity results in the blockade of downstream signaling events that are essential for CCDC42B's activity. Rapamycin's inhibition of the mammalian target of rapamycin (mTOR) kinase can also lead to an inhibition of CCDC42B by disrupting cell growth and proliferation processes with which CCDC42B might be involved. PD98059 and U0126, both MEK inhibitors, prevent the activation of the MAPK/ERK pathway, a common regulatory pathway for proteins like CCDC42B, thus inhibiting its function. Brefeldin A takes a different approach by disrupting protein trafficking through the inhibition of the ADP-ribosylation factor, blocking CCDC42B's transport within the cell. Lastly, Go6983 and Genistein, by inhibiting PKC and tyrosine kinases respectively, prevent the phosphorylation and subsequent regulation of proteins, which includes the inhibition of CCDC42B's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine inhibits a broad range of protein kinases. Inhibition of these kinases can lead to the functional inhibition of CCDC42B by preventing necessary phosphorylation events required for its activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of Protein Kinase C (PKC). PKC is involved in multiple signaling pathways that could regulate the activity of CCDC42B. Inhibition of PKC would thus lead to the functional inhibition of CCDC42B by disabling its regulation through PKC-dependent pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK pathway is implicated in cellular processes that CCDC42B may be involved in. Inhibiting JNK can lead to the functional inhibition of CCDC42B by disrupting these processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. As p38 MAP kinase is involved in stress responses and other cellular signaling pathways, its inhibition can lead to the functional inhibition of CCDC42B by preventing its participation in these pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K is central to many signaling pathways, including those that may govern the activity of CCDC42B. Inhibiting PI3K leads to the functional inhibition of CCDC42B by blocking signaling events crucial for its activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, and like LY294002, it prevents PI3K from initiating downstream signaling events. The functional inhibition of CCDC42B is achieved through the disruption of signaling pathways involving PI3K. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a kinase involved in cell growth and proliferation. mTOR signaling could be crucial for the functions of CCDC42B, and its inhibition can lead to the functional inhibition of CCDC42B by disrupting these essential cellular processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 prevents the activation of ERK and thus can lead to the functional inhibition of CCDC42B by blocking the MAPK/ERK pathway that may regulate its activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor that prevents the activation of the MAPK/ERK pathway. This pathway is often involved in regulating proteins like CCDC42B, and its inhibition by U0126 can lead to the functional inhibition of CCDC42B. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts protein trafficking by inhibiting the ADP-ribosylation factor (Arf). Disruption of protein trafficking can lead to the functional inhibition of CCDC42B by blocking its transport to the necessary cellular locations. | ||||||